The evidence base for PFAS health effects has strengthened considerably over the past decade. Key findings from the peer-reviewed literature:
Cancer mechanisms and epidemiology: PFOA's 2023 IARC Group 1 classification was based on "sufficient evidence" in humans for kidney cancer, with mechanistic evidence including epigenetic alterations, oxidative stress, immunosuppression, and receptor-mediated effects. The C8 study found a dose-response relationship between PFOA serum levels and kidney cancer incidence. Testicular cancer risk was elevated with odds ratios of 1.3-3.0 in occupational cohorts, with stronger associations at higher cumulative exposures.
Thyroid pathophysiology: PFAS compete with thyroid hormones (T3 and T4) for binding to transport proteins such as transthyretin and thyroid-binding globulin [1]. In vitro studies demonstrate direct inhibition of the sodium-iodide symporter and thyroid peroxidase. Population studies consistently show associations between PFAS quartiles and TSH elevation, particularly in women of reproductive age. Prenatal PFAS exposure has been associated with altered thyroid hormone levels in neonates, raising concerns about neurodevelopmental impacts.
Immunotoxicity dose-response: Grandjean's work in the Faroe Islands demonstrated that a doubling of PFAS serum concentration in children was associated with a roughly 50% reduction in vaccine antibody concentrations for tetanus and diphtheria [4]. The NTP systematic review graded the evidence as "high" confidence for immunosuppression in humans [5]. These immune effects occur at background exposure levels found in the general population, suggesting there may be no safe threshold.
Metabolic disruption: The JAMA Network Open study by Liu et al. followed 621 overweight or obese participants over two years [2]. Those in the highest tertile of baseline PFAS levels regained an average of 2.4 kg more weight than those in the lowest tertile, with the association strongest for PFOS. The mechanism appears to involve PPAR-alpha activation and disruption of lipid and energy metabolism. Elevated total cholesterol is one of the most consistently replicated findings across PFAS epidemiological studies, with effects observed at serum PFOA levels as low as 2 ng/mL.
Reproductive and developmental toxicity: A meta-analysis of 24 studies found that each 1 ng/mL increase in maternal PFOA was associated with an 18.9 g decrease in birth weight. Liew et al. reported associations between prenatal PFAS exposure and behavioral difficulties in children aged 5-9, including hyperactivity and conduct problems [3]. Animal studies demonstrate PFAS-induced disruption of estrogen, androgen, and progesterone signaling, with human data showing associations between PFAS exposure and longer time-to-pregnancy, endometriosis, and polycystic ovary syndrome.